How to Use a Noninferiority Trial Users' Guides to the Medical Literature

被引:72
作者
Mulla, Sohail M. [1 ]
Scott, Ian A. [3 ]
Jackevicius, Cynthia A. [4 ,5 ,6 ,7 ,8 ]
You, John J. [1 ,2 ,4 ]
Guyatt, Gordon H. [1 ,2 ]
机构
[1] McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada
[2] McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada
[3] Princess Alexandra Hosp, Dept Internal Med & Clin Epidemiol, Brisbane, Qld 4102, Australia
[4] Inst Clin Evaluat Sci, Toronto, ON, Canada
[5] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA
[6] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[7] Univ Hlth Network, Toronto, ON, Canada
[8] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2012年 / 308卷 / 24期
关键词
ATRIAL-FIBRILLATION; NON-INFERIORITY; OPEN-LABEL;
D O I
10.1001/2012.jama.11235
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical investigators are increasingly testing treatments that have the primary benefit of decreased burden or harms relative to an existing standard. The goal of the resulting randomized trials-called noninferiority trials-is to establish that the novel treatment's effectiveness is not substantially less than the existing standard. Conclusions from these trials are, however, based on noninferiority thresholds specified by authors whose judgments may not coincide with those of patients and clinicians. This article highlights issues related to validity, interpretation, and applicability of results specific to noninferiority trials. Suboptimal administration of standard treatment or exclusive reliance on the analyze-as-randomized approach that is standard for conventional superiority trials may produce misleading results in noninferiority trials. Clinicians should judge whether the novel treatment's impact on effectiveness outcomes-the prime reason for wanting to prescribe it-is sufficiently close to that of standard treatment that they are comfortable substituting it for the existing standard. Trading off desirable and undesirable consequences is an individual decision: given the benefits of a novel treatment, some patients may perceive the uncertainty regarding a reduction in treatment effectiveness as acceptable while others may not. JAMA 2012;308(24):2605-2611
引用
收藏
页码:2605 / 2611
页数:7
相关论文
共 21 条
[11]   Quality of reporting of noninferiority and equivalence randomized trials [J].
Le Henanff, A ;
Giraudeau, B ;
Baron, G ;
Ravaud, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (10) :1147-1151
[12]   Patient Values and Preferences in Decision Making for Antithrombotic Therapy: A Systematic Review Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines [J].
MacLean, Samantha ;
Mulla, Sohail ;
Akl, Elie A. ;
Jankowski, Milosz ;
Vandvik, Per Olav ;
Ebrahim, Shanil ;
McLeod, Shelley ;
Bhatnagar, Neera ;
Guyatt, Gordon H. .
CHEST, 2012, 141 (02) :E1S-E23S
[13]  
Montori VM, 2001, CAN MED ASSOC J, V165, P1339
[14]   Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial [J].
Nout, R. A. ;
Smit, V. T. H. B. M. ;
Putter, H. ;
Juergenliemk-Schulz, I. M. ;
Jobsen, J. J. ;
Lutgens, L. C. H. W. ;
van der Steen-Banasik, E. M. ;
Mens, J. W. M. ;
Slot, A. ;
Kroese, M. C. Stenfert ;
van Bunningen, B. N. F. M. ;
Ansink, A. C. ;
van Putten, W. L. J. ;
Creutzberg, C. L. .
LANCET, 2010, 375 (9717) :816-823
[15]   Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation [J].
Patel, Manesh R. ;
Mahaffey, Kenneth W. ;
Garg, Jyotsna ;
Pan, Guohua ;
Singer, Daniel E. ;
Hacke, Werner ;
Breithardt, Guenter ;
Halperin, Jonathan L. ;
Hankey, Graeme J. ;
Piccini, Jonathan P. ;
Becker, Richard C. ;
Nessel, Christopher C. ;
Paolini, John F. ;
Berkowitz, Scott D. ;
Fox, Keith A. A. ;
Califf, Robert M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :883-891
[16]   Reporting of Noninferiority and Equivalence Randomized Trials Extension of the CONSORT 2010 Statement [J].
Piaggio, Gilda ;
Elbourne, Diana R. ;
Pocock, Stuart J. ;
Evans, Stephen J. W. ;
Altman, Douglas G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (24) :2594-2604
[17]   Through the looking glass: understanding non-inferiority [J].
Schumi, Jennifer ;
Wittes, Janet T. .
TRIALS, 2011, 12
[18]   Non-inferiority trials: determining whether alternative treatments are good enough [J].
Scott, Ian A. .
MEDICAL JOURNAL OF AUSTRALIA, 2009, 190 (06) :326-330
[19]  
Temple R, 2010, GUIDANCE IND NONINFE
[20]   Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence - Results of the randomized cardiac insufficiency bisoprolol study (CIBIS) III [J].
Willenheimer, R ;
van Veldhuisen, DJ ;
Silke, B ;
Erdmann, E ;
Follath, F ;
Krum, H ;
Ponikowski, P ;
Skene, A ;
Van de Ven, L ;
Verkenne, P ;
Lechat, P .
CIRCULATION, 2005, 112 (16) :2426-2435